Positive News SentimentPositive NewsNASDAQ:ATHA Athira Pharma (ATHA) Stock Price, News & Analysis $2.57 0.00 (0.00%) (As of 09:51 AM ET) Add Compare Share Share Today's Range$2.54▼$2.5750-Day Range$1.92▼$2.7152-Week Range$1.33▼$4.30Volume8,473 shsAverage Volume292,356 shsMarket Capitalization$98.51 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Athira Pharma alerts: Email Address Athira Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside639.3% Upside$19.00 Price TargetShort InterestBearish2.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$100,208 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.79) to ($3.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.64 out of 5 starsMedical Sector398th out of 896 stocksBiological Products, Except Diagnostic Industry55th out of 152 stocks 3.5 Analyst's Opinion Consensus RatingAthira Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAthira Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Athira Pharma's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.86% of the float of Athira Pharma has been sold short.Short Interest Ratio / Days to CoverAthira Pharma has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Athira Pharma has recently increased by 13.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAthira Pharma does not currently pay a dividend.Dividend GrowthAthira Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATHA. Previous Next 2.7 News and Social Media Coverage News SentimentAthira Pharma has a news sentiment score of 1.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Athira Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for ATHA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Athira Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,208.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders19.80% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Athira Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Athira Pharma are expected to decrease in the coming year, from ($2.79) to ($3.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Athira Pharma is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Athira Pharma is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAthira Pharma has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Athira Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin Analytics50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the start of the year.So why are top hedge funds currently dumping their stocks? About Athira Pharma Stock (NASDAQ:ATHA)Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Read More ATHA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATHA Stock News HeadlinesJune 26, 2024 | insidertrades.comAthira Pharma, Inc. (NASDAQ:ATHA) Director Kelly A. Romano Purchases 15,000 SharesJune 27, 2024 | americanbankingnews.comKelly A. Romano Purchases 27,400 Shares of Athira Pharma, Inc. (NASDAQ:ATHA) StockJuly 5, 2024 | Chaikin Analytics (Ad)50-year Wall Street Legend Issues July Stock WarningJuly is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks – including NVDA – stumbling?June 12, 2024 | globenewswire.comAthira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease PatientsJune 10, 2024 | prnewswire.comGlancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ: ATHA)May 29, 2024 | globenewswire.comAthira Pharma to Participate in Upcoming June ConferencesMay 20, 2024 | markets.businessinsider.comBuy Rating Affirmed on Athira Pharma Amid Promising Alzheimer’s Drug Developments and Strategic AdvancementsMay 17, 2024 | globenewswire.comAthira Pharma Announces Proposed Settlement of Stockholder Derivative ActionJuly 5, 2024 | Chaikin Analytics (Ad)50-year Wall Street Legend Issues July Stock WarningJuly is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks – including NVDA – stumbling?May 17, 2024 | bizjournals.comAthira names new chief medical officer ahead of release of key trial dataMay 16, 2024 | finanznachrichten.deAthira Pharma, Inc.: Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business UpdatesMay 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Celcuity (CELC) and ATAI Life Sciences (ATAI)May 16, 2024 | msn.comATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024May 15, 2024 | globenewswire.comAthira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business UpdatesMay 2, 2024 | globenewswire.comAthira Pharma to Participate in Upcoming May ConferencesApril 27, 2024 | seekingalpha.comATHA Athira Pharma, Inc.April 23, 2024 | finance.yahoo.comOne Athira Pharma Insider Raised Their Stake In The Previous YearApril 17, 2024 | msn.comAthira Pharma (ATHA) Price Target Increased by 7.49% to 7.57April 15, 2024 | finanznachrichten.deAthira Pharma, Inc.: Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical OfficerApril 15, 2024 | markets.businessinsider.comAthira Pharma Appoints Javier San Martin As New Chief Medical OfficerApril 15, 2024 | globenewswire.comAthira Pharma Appoints Javier San Martin, M.D., as Chief Medical OfficerApril 11, 2024 | finanznachrichten.deAthira Pharma, Inc.: Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's DiseaseApril 11, 2024 | finance.yahoo.comAthira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s DiseaseApril 11, 2024 | globenewswire.comAthira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's DiseaseApril 3, 2024 | globenewswire.comAthira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual MeetingMarch 20, 2024 | finance.yahoo.comAthira Pharma, Inc. (ATHA)March 8, 2024 | finance.yahoo.comAthira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International ConferenceSee More Headlines Receive ATHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/05/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ATHA CUSIPN/A CIK1620463 Webathira.com Phone425-620-8501FaxN/AEmployees65Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$19.00 Low Stock Price Target$19.00 Potential Upside/Downside+639.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-80.59% Return on Assets-67.70% Debt Debt-to-Equity RatioN/A Current Ratio5.03 Quick Ratio5.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / Book0.75Miscellaneous Outstanding Shares38,330,000Free Float30,740,000Market Cap$98.51 million OptionableOptionable Beta2.90 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Mark J. Litton M.B.A. (Age 56)Ph.D., President, CEO & Director Comp: $882.7kMr. Andrew W. Gengos (Age 60)CFO & Chief Business Officer Comp: $396.16kMs. Rachel P. Lenington M.B.A. (Age 51)Chief Development Officer & COO Comp: $578kDr. Kevin Church Ph.D. (Age 39)Chief Scientific Officer Comp: $123.67kMs. Julie RathbunHead of Investor RelationsMr. Mark F. Worthington J.D. (Age 58)General Counsel & Corporate Secretary Comp: $503.83kMs. Samantha WillingChief People OfficerDr. Javier San Martin M.D. (Age 59)Chief Medical Officer More ExecutivesKey CompetitorsVaxartNASDAQ:VXRTPassage BioNASDAQ:PASGAligos TherapeuticsNASDAQ:ALGSEditas MedicineNASDAQ:EDITFate TherapeuticsNASDAQ:FATEView All CompetitorsInsiders & InstitutionsKelly A RomanoBought 27,400 shares on 6/24/2024Total: $66,308.00 ($2.42/share)Kelly A RomanoBought 15,000 shares on 6/21/2024Total: $33,900.00 ($2.26/share)Jacobs Levy Equity Management Inc.Bought 227,278 shares on 5/16/2024Ownership: 1.298%Vanguard Group Inc.Sold 64,020 shares on 5/10/2024Ownership: 4.264%Acadian Asset Management LLCBought 405,793 shares on 5/10/2024Ownership: 1.435%View All Insider TransactionsView All Institutional Transactions ATHA Stock Analysis - Frequently Asked Questions Should I buy or sell Athira Pharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ATHA shares. View ATHA analyst ratings or view top-rated stocks. What is Athira Pharma's stock price target for 2024? 1 equities research analysts have issued twelve-month target prices for Athira Pharma's stock. Their ATHA share price targets range from $19.00 to $19.00. On average, they predict the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 639.3% from the stock's current price. View analysts price targets for ATHA or view top-rated stocks among Wall Street analysts. How have ATHA shares performed in 2024? Athira Pharma's stock was trading at $2.43 at the beginning of 2024. Since then, ATHA stock has increased by 5.8% and is now trading at $2.57. View the best growth stocks for 2024 here. Are investors shorting Athira Pharma? Athira Pharma saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 1,010,000 shares, an increase of 13.5% from the May 31st total of 889,500 shares. Based on an average daily volume of 173,900 shares, the short-interest ratio is presently 5.8 days. Approximately 2.9% of the shares of the stock are short sold. View Athira Pharma's Short Interest. When is Athira Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ATHA earnings forecast. How were Athira Pharma's earnings last quarter? Athira Pharma, Inc. (NASDAQ:ATHA) posted its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.80) by $0.11. What ETF holds Athira Pharma's stock? Simplify Propel Opportunities ETF holds 1,492,792 shares of ATHA stock, representing 3.85% of its portfolio. What other stocks do shareholders of Athira Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR). When did Athira Pharma IPO? Athira Pharma (ATHA) raised $160 million in an IPO on Friday, September 18th 2020. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel acted as the underwriters for the IPO and JMP Securities was co-manager. How do I buy shares of Athira Pharma? Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATHA) was last updated on 7/5/2024 by MarketBeat.com Staff From Our Partners50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATHA Stock Alerts